Timber pharmaceuticals receives european orphan drug designation for tmb-001 in x-linked recessive ichthyosis

Company progressing with pivotal phase 3 ascend clinical trial in the u.s., canada, italy, france, and germany
TMBR Ratings Summary
TMBR Quant Ranking